We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Study to Monitor Abused Opioid Medications

By HospiMedica staff writers
Posted on 08 Jul 2002
A US program has been initiated to study the prevalence of abuse and the diversion of controlled opioid precription medications with recognized abuse potential.

Called the RADARS system (researched abuse, diversion, and addiction-related surveillance), the program is designed to obtain valuable quantitative and qualitative information on the relative rates of abuse, addiction, and diversion of commonly prescribed opioid pain medications, data that currently are not available. More...
Initially, the system will monitor six medications with abuse potential: morphine, buprenorphine, fentanyl, hydrocodone, hydromorphone, and oxycodone. As experience with the system accumulates, other types of medications, such as benzodiazepines, will be added to the list.

The program was established by Purdue Pharma (Stamford, CT, USA). The company is contracting with universities and other agencies to conduct drug studies. Two studies will collect data on OxyContin in areas where heavy abuse of this drug has been found. Researchers will also collect information from pain specialists, addiction treatment specialists, and directors of addiction treatment programs. The data generated will help the health-care community, law enforcement, the public, and the pharmaceutical industry to better understand the problems of abuse and diversion of prescription drugs. Data will also be used to help design and assess prevention and intervention programs.

"A comprehensive surveillance system is needed to look at these data and establish a scientific foundation for developing more effective prevention and intervention efforts,” said Sidney H. Schnoll, M.D., Ph.D., medical director, health policy, at Purdue Pharma. Dr. Schnoll is a nationally recognized expert on addiction medicine.


Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Multi-Chamber Washer-Disinfector
WD 390
New
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.